Navigation Links
MedAvante Central Ratings Selected For Cerecor Investigational MDD Study
Date:12/2/2013

HAMILTON, N.J., Dec. 2, 2013 /PRNewswire/ -- MedAvante, Inc., the world's leading provider of centralized assessments and monitoring in clinical trials of treatments for central nervous system (CNS) disorders, announced that biopharmaceutical company Cerecor Inc. will use MedAvante Central Ratings in the phase 2 clinical study of CERC-301, an investigational drug intended for the adjunctive treatment of subjects with major depressive disorder (MDD) who have not adequately responded to their current therapy and report recent suicidal ideation.

"A new treatment with potential for rapid onset of action for severely depressed, treatment resistant patients is urgently needed," said James Vornov, MD, PhD, Cerecor SVP, Clinical Development and Regulatory Affairs.

"In this Phase 2 study of CERC-301, an oral, selective NMDA receptor subunit 2B (NR2B) antagonist, we will use the blinded, independent MedAvante Central Raters to maximize signal detection through objective and standardized outcome measurement," he said.

Central Ratings assessments of study subjects at investigative research sites will be conducted by experienced and continuously trained MedAvante clinicians, confirming symptom severity prior to randomization and administering the trial's primary endpoint measure.

"MedAvante has unique clinical and operational expertise and technology to handle the sensitive requirements of our study," said Dr. Vornov.  "They utilize a robust process to standardize the assessments and ensure that the Central Raters are fully blinded to protocol and visit history."

"MedAvante Central Ratings attack the root causes of the intractable problem of a high percentage of CNS trials failing to determine conclusive outcomes," said Paul M. Gilbert, co-founder and CEO of MedAvante.  "Because we provide a smaller number of trained clinical raters to perform assessments in place of different raters at every site, we can minimize variability of study data and avoid perception biases which can increase placebo response and reduce observed drug effect," he said.  "We are proud to bring these capabilities to the Cerecor study."

About MedAvante, Inc.

MedAvante is the leading global provider of centralized expert psychiatric and neurocognition rating and monitoring services to the pharmaceutical, biotechnology and medical device industries.  MedAvante central trial services help sponsors enhance assay sensitivity for increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. Supported by operational teams in the US, Germany, Russia and Japan, MedAvante clinicians located in 31 countries and speaking 26 languages deliver Central Trial Services in 41 countries worldwide.
For more information, please visit www.medavante.com.

About Cerecor Inc.

Cerecor Inc. is a privately held clinical stage biopharmaceutical company developing prescription pharmaceuticals that work in the human nervous system and which address the needs of underserved patient segments of major diseases.  We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders.  www.cerecor.com


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. A molecule central to diabetes is uncovered
3. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
4. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
5. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
6. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at ReportsnReports.com
9. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks
10. Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sullefficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
11. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):